ANALYTICAL & LAB EQUIPMENT
LIFE FROM A LAB
Funding for a new AI solution from Telesis Bio promises to make the creation of in-house biologics mainstream
The Gibson Sola platform will put the creation of biologics in the hands of researchers A
lmost all companies involved in biological or drug discovery are now using AI tools to design
molecules, and a large cash injection into a recently developed platform from synthetic biology company Telesis Bio promises to signifi cantly accelerate activity of this sort. The solution, a platform called Gibson Sola, has just received US$21m in funding from venture capitalist fi rm Northpond Ventures, and big hitter investment and consultancy fi rm Novalis Life Sciences. The injection will help to drive rapid
This illustration shows the Sola platform throughput
commericalisation of the platform. The platform uses AI to create biologics overnight, the result being faster more reliable and innovative solutions, according to the company. The products created will be for use in biologics, vaccine and cell therapy research and development. After an extensive development period, the platform was launched to all customers in January of 2025.
CRITICAL RAW MATERIALS DNA and mRNA are critical raw materials that power therapeutic
research and molecular diagnostics, and demand for high-quality nucleic acids from researchers and scientists is large and growing rapidly. The platform will mean researchers do not have to rely on an often complicated external supply chain since it allows them to make DNA and mRNA overnight in their own labs using standard liquid handling equipment. The platform and software suite can be used to deploy automated on-site synthesis solutions for a variety of targets, molecules, as well as applications, from low- to high- throughput.
18
www.scientistlive.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
